数字乳腺断层合成上结构扭曲的恶性结局:系统综述与Meta分析
该系统综述与Meta分析纳入13项回顾性观察研究、共857个数字乳腺断层合成(DBT)上无已知原因的结构扭曲(AD),汇总恶性阳性预测值(PPV)为34.6%(95%CI 24.5-46.3%),其中浸润性癌PPV为34%、导管原位癌为5%;277个恶性AD中217个(78.3%)有超声对应发现。作者结论认为DBT上无已知原因的AD恶性PPV高,应进行组织取样,且应行超声寻找对应发现,但无超声对应发现不能免除活检。
要点
- DBT上无已知原因的AD(BI-RADS 4或5类)汇总恶性PPV为34.6%,作者结论认为应进行组织取样。
- 恶性AD中78.3%(217/277)有超声对应发现,但无超声对应发现不能免除活检。
- 857个AD中良性病变235个(27.4%)、高危病变282个(32.9%)、非乳腺转移性病变1个(0.1%)。
核心结论
- DBT上无已知原因的结构扭曲汇总恶性PPV为34.6%(95%CI 24.5-46.3%),作者结论认为应进行组织取样。
- 作者临床影响指出:对DBT上无已知原因的结构扭曲应行针刺活检;因多数恶性扭曲在超声上有对应发现,应行超声寻找对应发现,但无对应发现不能免除活检。
研究设计与样本
- 系统综述与Meta分析,检索Embase、MEDLINE和Evidence-Based Medicine Reviews数据库截至2020年7月15日发表的所有研究。
- 纳入评估DBT上无已知原因、判定为BI-RADS 4或5类的结构扭曲恶性率的研究,共纳入13项回顾性观察研究、857个结构扭曲。
- 以空芯针活检或手术病理作为病灶诊断参考标准,采用随机效应模型估计汇总PPV及95%CI。
关键影像表现/征象
- 857个结构扭曲中339个为乳腺恶性肿瘤,汇总恶性PPV为34.6%(95%CI 24.5-46.3%)。
- 浸润性恶性肿瘤汇总PPV为34%(95%CI 25-45%),导管原位癌为5%(95%CI 4-7%)。
- 857个结构扭曲中良性病变235个(27.4%)、高危病变282个(32.9%)、非乳腺转移性病变1个(0.1%)。
- 在评估超声对应发现的研究中,277个恶性结构扭曲有217个(78.3%)存在超声对应发现。
诊断标准与关键数值
- 纳入标准为DBT上无已知原因、判定为BI-RADS 4或5类的结构扭曲,以空芯针活检或手术病理为参考标准。
- 汇总恶性PPV为34.6%(95%CI 24.5-46.3%),浸润性癌PPV为34%(95%CI 25-45%),导管原位癌PPV为5%(95%CI 4-7%)。
临床应用与阅片要点
- 作者临床影响指出:对DBT上无已知原因的结构扭曲应行针刺活检。
- 作者临床影响指出:因多数恶性扭曲有超声对应发现,应行超声寻找对应发现,但无对应发现不能免除活检。
局限性
- 纳入的13项研究均为回顾性观察研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. The literature has reported varying rates of malignancy for architectural distortion (AD) on digital breast tomosynthesis (DBT). OBJECTIVE. The purpose of this study was to evaluate the PPV for malignancy of AD on DBT without a known cause and to assess the presence of an ultrasound (US) correlate for malignant AD through systematic review and meta-analysis of the literature. EVIDENCE ACQUISITION. This meta-analysis included all studies published in Em-base, MEDLINE, and Evidence-Based Medicine Reviews databases through July 15, 2020, that assessed the rate of malignancy in patients with AD on DBT without a known cause that was deemed BI-RADS category 4 or 5. Rates of benign or high-risk lesions and the presence of a US correlate for malignant AD were assessed. Core needle biopsy or surgical pathology was used as the reference standard for lesion diagnosis. The pooled PPV and 95% CI were estimated using a random-effects model. EVIDENCE SYNTHESIS. Thirteen retrospective, observational studies were included, yielding 857 ADs seen on DBT. Of the 857 ADs, 339 were breast malignancies, yielding a pooled PPV for malignancy of 34.6% (95% CI, 24.5-46.3%). The pooled PPV for invasive malignancy was 34% (95% CI, 25-45%) and for ductal carcinoma in situ was 5% (95% CI, 4-7%). Of the 857 ADs, 235 (27.4%) were benign lesions, 282 (32.9%) were high-risk lesions, and 1 (0.1%) was a nonbreast metastatic lesion. From the studies that assessed for US correlates, 217 of 277 malignant ADs (78.3%) had a US correlate. CONCLUSION. The pooled PPV for malignancy of AD on DBT without a known cause is high at 34.6%, warranting tissue sampling. CLINICAL IMPACT. A needle biopsy should be performed for ADs on DBT without a known cause. Because most malignant distortions have a corresponding finding on US, a US examination should be performed to look for a correlate, but the absence of a correlate does not obviate a biopsy.
引用
- Choudhery S, Johnson MP, Larson NB, et al. Malignant Outcomes of Architectural Distortion on Tomosynthesis: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2020. PMID: 32966111. doi:10.2214/AJR.20.23935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。